Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure - PubMed (original) (raw)
Clinical Trial
. 2007 Mar-Apr;24(2):346-52.
doi: 10.1007/BF02849903.
Affiliations
- PMID: 17565925
- DOI: 10.1007/BF02849903
Clinical Trial
Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure
Mehmet Kanbay et al. Adv Ther. 2007 Mar-Apr.
Abstract
It is well known that epoetin alfa increases serum endothelin (ET)-1 and blood pressure. No data are available, however, on the effects of darbepoetin alfa on serum ET-1 and blood pressure. This study was conducted to compare the effects of darbepoetin alfa and epoetin alfa on serum ET-1 and blood pressure in patients on hemodialysis (HD). A total of 42 patients on HD were included in the study. Serum samples for measuring levels of ET-1 were taken 30 min after administration of epoetin alfa. After blood samples had been taken from all patients, epoetin alfa was changed to darbepoetin alfa. Three months after the start of darbepoetin alfa treatment, blood samples were taken to measure the same parameters. Mean arterial blood pressure was measured before recombinant human erythropoietin (EPO) administration and 30 min after EPO administration while patients were taking epoetin alfa or darbepoetin alfa. Injection of epoetin alfa or darbepoetin alfa significantly increased serum ET-1 levels compared with levels in those patients who were not on EPO therapy (P<.05). When the effects of epoetin alfa on serum ET-1 level were compared with those of darbepoetin alfa, the 2 types of EPO were found to increase serum ET-1 levels similarly (P>.05). Administration of epoetin alfa or darbepoetin alfa increased systolic and diastolic blood pressures significantly over values in the control group (P<.05). Serum systolic and diastolic blood pressures increased similarly after injection of epoetin alfa or darbepoetin alfa. Administration of darbepoetin alfa increased blood pressure in patients on HD in a way that was positively correlated with enhanced ET-1 release; a similar correlation was noted with epoetin alfa.
Similar articles
- Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC, Chang TI, Mitani AA, Wilhelm-Leen ER, Ding V, Chertow GM, Brookhart MA, Goldstein BA. Winkelmayer WC, et al. Am J Kidney Dis. 2015 Jul;66(1):106-13. doi: 10.1053/j.ajkd.2015.02.339. Epub 2015 May 2. Am J Kidney Dis. 2015. PMID: 25943715 Free PMC article. - Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC. Chen HH, et al. J Nephrol. 2008 Jul-Aug;21(4):543-9. J Nephrol. 2008. PMID: 18651544 Clinical Trial. - Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER, Winkelmayer WC. Wilhelm-Leen ER, et al. Am J Kidney Dis. 2015 Jul;66(1):69-74. doi: 10.1053/j.ajkd.2014.12.012. Epub 2015 Jan 28. Am J Kidney Dis. 2015. PMID: 25636816 Free PMC article. Review. - Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis.
Brown JN, Kemp DW, Brice KR. Brown JN, et al. Pharmacotherapy. 2009 Apr;29(4):468-72. doi: 10.1592/phco.29.4.468. Pharmacotherapy. 2009. PMID: 19323622 - A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C. Wilson J, et al. Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. doi: 10.3310/hta11130. Health Technol Assess. 2007. PMID: 17408534 Review.
Cited by
- Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N, Jachimowicz E, Wojchowski DM. Rainville N, et al. Expert Opin Ther Targets. 2016;20(3):287-301. doi: 10.1517/14728222.2016.1090975. Epub 2015 Sep 30. Expert Opin Ther Targets. 2016. PMID: 26419263 Free PMC article. Review. - Blood Haemoglobin Concentration Is Directly and Independently Related with Pulse Wave Velocity, a Measure of Large Artery Stiffness.
Choudhary MK, Bouquin H, Hytönen J, Koskela JK, Niemelä O, Nevalainen PI, Mustonen J, Pörsti I. Choudhary MK, et al. J Clin Med. 2023 Dec 11;12(24):7623. doi: 10.3390/jcm12247623. J Clin Med. 2023. PMID: 38137695 Free PMC article. - Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies.
Maiese K, Chong ZZ, Li F, Shang YC. Maiese K, et al. Prog Neurobiol. 2008 Jun;85(2):194-213. doi: 10.1016/j.pneurobio.2008.02.002. Epub 2008 Mar 4. Prog Neurobiol. 2008. PMID: 18396368 Free PMC article. Review. - Erythropoietin and oxidative stress.
Maiese K, Chong ZZ, Hou J, Shang YC. Maiese K, et al. Curr Neurovasc Res. 2008 May;5(2):125-42. doi: 10.2174/156720208784310231. Curr Neurovasc Res. 2008. PMID: 18473829 Free PMC article. Review. - Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients.
Suttorp MM, Hoekstra T, Mittelman M, Ott I, Franssen CF, Dekker FW. Suttorp MM, et al. PLoS One. 2013 Dec 31;8(12):e84848. doi: 10.1371/journal.pone.0084848. eCollection 2013. PLoS One. 2013. PMID: 24391978 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials